Hormone therapyFDA-approvedSecond-line
Abiraterone
How it works
Blocks the production of testosterone in the body, slowing prostate cancer growth.
Cancer types
Prostate Cancer— All patients
Efficacy
In clinical trials, abiraterone improved overall survival and reduced disease progression in men with metastatic castration-resistant prostate cancer.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Olaparib and Abiraterone Combination Therapy for Prostate Cancer | Prostate Cancer | phase-2 | The 1-year radiographic progression-free survival rate was 77.7% (95% CI: 63.4-95.3%). | Source → |
| Evaluating a New Medicine for Men with Advanced Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Abiraterone, Apalutamide, and Prednisone in Treating Hormone-Naive Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Testing Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Low-Dose Abiraterone May Be a Feasible Alternative for Prostate Cancer Treatment | Prostate Cancer | phase-3 | Median PSA-PFS was 5.7 months with low-dose versus 3.8 months with standard-dose AA. | Source → |
| New Treatment Combination Shows Promise for Men with Advanced Prostate Cancer | Prostate Cancer | phase-3 | Median radiographic progression-free survival was 38.6 months in the niraparib + AAP group versus 8.3 months in the placebo + AAP group. | Source → |
| Testing Xaluritamig Plus Abiraterone for Metastatic Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Capivasertib and Abiraterone for Prostate Cancer with PTEN Deficiency | Prostate Cancer | phase-3 | — | Source → |
| Abiraterone and Antiandrogen Therapy for Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Testing a New Treatment for Advanced Prostate Cancer | Prostate Cancer | phase-1 | — | Source → |
| Olaparib and Abiraterone Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Abiraterone Acetate May Help Fight Prostate Cancer by Triggering Stress Response | Prostate Cancer | lab-study | AA induced concentration/time-dependent cytotoxicity in LNCaP cells (24 h IC₅₀ = 4.8 μM) and 22Rv1 cells (24 h IC₅₀ = 15.2 μM) and proliferation decreased by 54.1% and 7.3% at 4.8 μM, respectively. | Source → |
| Genetic Link to Abiraterone Dosage Identified in Prostate Cancer Study | Prostate Cancer | phase-3 | — | Source → |
| Abiraterone and Enzalutamide Show Similar Outcomes in Prostate Cancer | Prostate Cancer | observational | Median overall survival was 36.2 months for both abiraterone and enzalutamide. | Source → |
| Combining Medications May Help Prostate Cancer Patients | Prostate Cancer | phase-3 | The primary endpoint was met, with a significant improvement in radiographic progression-free survival observed, with a hazard ratio of 0.63. | Source → |
| Combining Trastuzumab Deruxtecan and Abiraterone Shows Promise in Prostate Cancer | Prostate Cancer | observational | — | Source → |
| Enzalutamide May Offer Better Survival for Prostate Cancer Patients | Prostate Cancer | observational | Enzalutamide-treated patients had longer overall survival in the first-line setting (HR: 0.84) and the second-line setting (HR: 0.88). | Source → |
| New Delivery System for Prostate Cancer Treatment Shows Promise | Prostate Cancer | lab-study | The dissolution study demonstrated significantly higher ABT release from ABT-ssSNEDDS in comparison to free ABT after 2 h in pH 1.2 and 6.8 pH buffer. | Source → |
| Comorbidities Affect Abiraterone Treatment in Prostate Cancer | Prostate Cancer | meta-analysis | — | Source → |
| Modified Monitoring of Abiraterone May Reduce Liver Damage in Prostate Cancer Patients | Prostate Cancer | observational | — | Source → |
| Comparing Prostate Cancer Treatments: Abiraterone, Enzalutamide, and Apalutamide | Prostate Cancer | observational | Abiraterone was significantly better in 99% PSA decline achievement compared to apalutamide (72% vs. 57%, p = 0.003). | Source → |
| Abiraterone Resistance in Prostate Cancer Linked to CENPK Splice Variant | Prostate Cancer | lab-study | — | Source → |
| Olaparib and Abiraterone Combination Therapy for Prostate Cancer | Prostate Cancer | review | — | Source → |
| Abiraterone Treatment in Prostate Cancer: Early Response Matters | Prostate Cancer | phase-2 | Those patients with hetero-responding disease had significantly different PFS compared to the responding and non-responding groups (hazard ratio: responding group = reference, hetero-responding group = 4.0, non-responding group = 5.8; p < 0.0001). | Source → |
| Comparing Treatments for Advanced Prostate Cancer | Prostate Cancer | observational | Patients initiating enzalutamide had a 0.90-month longer overall survival compared to those initiating abiraterone acetate at 4 years. | Source → |
| Long-term effects of prostate cancer treatment studied | Prostate Cancer | phase-2 | A significant association between higher abiraterone acetate concentrations and better clinical benefit was observed (p = 0.041). | Source → |
| Abiraterone Efficacy Predicted by Prostate Cancer Biomarker | Prostate Cancer | observational | The median PSA-PFS was 11.43 months versus 26.43 months in patients with KI67 ≥ 30% versus those with KI67 < 30%. | Source → |
| Abiraterone May Cause Heart Rhythm Problem in Some Patients | Prostate Cancer | observational | — | Source → |
| New Treatment Combination for Advanced Prostate Cancer | Prostate Cancer | phase-3 | The median radiographic progression-free survival was 25 months for olaparib plus abiraterone versus 17 months for placebo plus abiraterone. | Source → |
| New Study Compares Effectiveness of Two Cancer Drugs for Prostate Cancer | Prostate Cancer | phase-3 | The median PSA response rate was -65.4% with abiraterone and -78.8% with enzalutamide. | Source → |
| Genetic variant linked to poorer prostate cancer treatment outcomes | Prostate Cancer | observational | A total of 54 patients (20%) had the variant, which was associated with a significantly worse overall survival (HR = 1.71, 95% CI 1.09 - 2.68, p = 0.019) and time to progression (HR = 1.50, 95% CI 1.08 - 2.09, p = 0.016), and was related with a significantly less frequent PSA response (OR = 0.48, 95% CI 0.24 - 0.96, p = 0.038). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.